Drugs / HYALOGYN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04560283 | Sep 2016 → May 2020 | puerperal disorder, sexual disorder | Ospedale Policlinico San Martino | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYALOGYN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04560283 ↗ |
| Known as | HYDEAL-D | “Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks” NCT04560283 ↗ |
| Modality | Other / unclassified | “prolonged-release hyaluronic acid derivative vaginal gel” PMID 34477473 ↗ Dec 2021 |